To secure capital growth from a portfolio of securities of companies engaged in Health and Pharmaceuticals and Biotechnology.
Name | % Net Assets |
---|---|
PFIZER INC | 0.0% |
ASTRAZENECA | 0.0% |
SANOFI-AVENTIS | 0.0% |
ABBOTT LABORATORIES | 0.0% |
MERCK & CO INC | 0.0% |
ROCHE HLDG AG | 0.0% |
NOVARTIS AG | 0.0% |
GLAXOSMITHKLINE | 0.0% |
JOHNSON & JOHNSON | 0.0% |
WYETH | 0.0% |
Key | % Net Assets |
---|---|
PFIZER INC | 0.0% |
ASTRAZENECA | 0.0% |
SANOFI-AVENTIS | 0.0% |
ABBOTT LABORATORIES | 0.0% |
Other | 100% |
Date | 21-Nov-2024 |
---|---|
NAV | 114.60p |
Currency | GBP |
Change | 1.40p |
% | 1.24% |
YTD change | 3.10p |
YTD % | 2.78% |
Fund Inception | 21/11/2000 |
---|---|
Fund Manager | Ali Toutounchi |
TER | 1.15 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.08 |
You are here: research